Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4 + CAR T-cell antitumor activity

CD4 T cells and CD4 chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating how and when CD4 T cells promote tumor regression are incompletely understood. With the help of functional intravital imagin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature cancer 2023-07, Vol.4 (7), p.968-983
Hauptverfasser: Boulch, Morgane, Cazaux, Marine, Cuffel, Alexis, Guerin, Marion V, Garcia, Zacarias, Alonso, Ruby, Lemaître, Fabrice, Beer, Alexander, Corre, Béatrice, Menger, Laurie, Grandjean, Capucine L, Morin, Florence, Thieblemont, Catherine, Caillat-Zucman, Sophie, Bousso, Philippe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CD4 T cells and CD4 chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating how and when CD4 T cells promote tumor regression are incompletely understood. With the help of functional intravital imaging, we report that interferon (IFN)-γ production but not perforin-mediated cytotoxicity was the dominant mechanism for tumor elimination by anti-CD19 CD4 CAR T cells. Mechanistically, mouse or human CD4 CAR T-cell-derived IFN-γ diffused extensively to act on tumor cells at distance selectively killing tumors sensitive to cytokine-induced apoptosis, including antigen-negative variants. In anti-CD19 CAR T-cell-treated patients exhibiting elevated CAR CD4:CD8 ratios, strong induction of serum IFN-γ was associated with increased survival. We propose that the sensitivity of tumor cells to the pro-apoptotic activity of IFN-γ is a major determinant of CD4 CAR T-cell efficacy and may be considered to guide the use of CD4 T cells during immunotherapy.
ISSN:2662-1347
2662-1347
DOI:10.1038/s43018-023-00570-7